Fundz
Funding, M&A and exec moves matched to your market — guaranteed to pay for itself in a year, or we refund it. See terms for full details.See plans →

Henlius and Sandoz Enter Strategic Collaboration for Up to 10 Biosimilar Antibody Products

Aug 17, 2026•about 8 hours ago

Contract Type

partnership

ShanghaiBiotechnologyHealth CareTherapeuticsBiopharma

Description

Henlius has announced a strategic collaboration with Sandoz, expanding their oncology and biologics partnership. This agreement covers the development of up to 10 new biosimilars, potentially bringing Henlius up to $322 million in payments. The collaboration includes exclusive rights for registration and commercialization outside China.

Company Information

Company

Shanghai Henlius Biotech

Location

Shanghai, China

About

Shanghai Henlius Biotech, Inc. is a biopharmaceutical company focused on developing biosimilars and novel biological medicines. The company specializes in recombinant monoclonal antibodies and aims to address unmet medical needs through research and development. Henlius is committed to enhancing patient access to affordable and high-quality treatments globally. Their product portfolio includes investigational biopharmaceuticals for various therapeutic areas, including oncology.

Predictive Intelligence
Strategic

ML-powered predictions for Shanghai Henlius Biotech's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.